Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma

NCT03326388 is registered in ClinicalTrials.gov with Great Ormond Street Hospital for Children NHS Foundation Trust as lead sponsor.

NCT NCT03326388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03326388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
Lead sponsor
Great Ormond Street Hospital for Children NHS Foundation Trust
Phase
Phase 1/2
Overall status
Completed
Start date
September 26, 2019
Completion date
February 14, 2024
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis type 1, optic nerve glioma, plexiform neurofibroma